aptamer

The next challenge is to effectively target the new aptamer at real cancers.

They also tried it in a pig that had been given an aptamer blood thinner compound.

The process can be repeated, allowing for significant enrichment of the desired aptamer.

After the administration of the aptamer into rhesus monkeys, no toxic effects where exhibited.

This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.

He isolated the first aptamer (term he used for the first time).

When trying to stabilize the aptamer by chemical modification the L-enantiomer failed, but the 3-5-phosporamidate was successful.

Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched active control agent.

Riboswitches are often conceptually divided into two parts: an aptamer and an expression platform.

Peptide aptamer selection can be made using different systems, but the most used is currently the yeast two-hybrid system.

To date, this will be the first known use of an aptamer in humans delivered by the subcutaneous route of administration.

Adding an unnatural base to a standard aptamer can increae its ability bind to target molecules.

If we can use this aptamer to target the carcinogenic protein, we might be talking about much less radical surgery in the future.

The Company is unique in its focus on developing aptamer therapeutics paired with agents that can directly modulate their activity.

Since the discovery of aptamers, many researchers have used aptamer selection as a means for application and discovery.

The preQ riboswitch is distinguished by its unusually small aptamer, compared to other riboswitches.

These systems comprise aptamer therapeutics that can be directly controlled by a specific and matched oligonucleotide agent.

Application of Aptamer technology to the isolation of specific compounds from Agri-food products.

The team tested these antidote molecules against eight different aptamer compounds in test tubes and found it controlled the activity of all of them.

SPR imaging platform would be a good choice to characterize aptamer -protein interactions.

Glycine riboswitches usually consist of two metabolite-binding aptamer domains with similar structures in tandem.

The x-ray crystal structure of the TPP riboswitch aptamer has been solved.

An example is a tenascin-binding aptamer under development by Schering AG for cancer imaging.

The aptamer binds to and neutralizes a protein that promotes the growth of the leaky blood vessels in the eye that cause the disease.

Only few hydrophobic unnatural base as a fifth base significantly augment the aptamer affinity to target proteins.